R&D channel feed

Astel­las scores a pair of tri­al wins for menopausal hot flash med, rais­ing the pitch of loom­ing Bay­er stand­off

5 years ago

Im­mu­nic's lead drug fails to im­press in 2 sep­a­rate tri­als — and it's blam­ing some of its woes on the pan­dem­ic

5 years ago

5 years lat­er, CAR-T pi­o­neer Kym­ri­ah of­fers jaw-drop­ping ev­i­dence of durable re­mis­sions — even as it still proves a tough sell

5 years ago
Pharma

With long-term da­ta in hand, Vivek Ra­maswamy's Der­ma­vant team dash­es to the goal line with top­i­cal pso­ri­a­sis con­tender

5 years ago

Eli Lil­ly dan­gles $960M for Rigel's RIPK in­hibitor, tak­ing on Sanofi and De­nali in neu­rode­gen­er­a­tion

5 years ago

Mov­ing up the lines, As­traZeneca stakes an­oth­er PhI­II win for Lyn­parza as ad­ju­vant breast can­cer ther­a­py

5 years ago

Blue­bird hits the brakes on Lenti­Glo­bin stud­ies, Zyn­te­glo mar­ket­ing af­ter AML, myelodys­plas­tic syn­drome cas­es spur fresh safe­ty con­cerns

5 years ago
Cell/Gene Tx

Take­da suc­ceeds where oth­er phar­mas have failed with PhI­II win for cy­tomegalovirus castoff marib­avir

5 years ago

Gy­ro­scope posts ear­ly win with gene ther­a­py for AMD, giv­ing hope for its im­mune com­ple­ment sys­tem tar­get

5 years ago

De­nali un­veil proof-of-con­cept da­ta for brain de­liv­ery tech in rare dis­ease, with eyes on much big­ger in­di­ca­tions

5 years ago

Roche touts less oner­ous sched­ule for its in-the-eye in­jec­tion faricimab, hop­ing to sweet­en the sales pitch over Eylea

5 years ago

Am­i­cus shares slammed as lead PhI­II drug fails a key head-to-head test for Pompe dis­ease — but the CEO still projects an FDA OK and bright fu­ture

5 years ago
FDA+

AC Im­mune has 're­mark­able' Alzheimer's vac­cine da­ta. Just don't ask to see them

5 years ago

All in on ide-cel, Bris­tol My­ers Squibb writes off $470M as sec­ond BC­MA CAR-T is eject­ed from the pipeline

5 years ago

No­vo Nordisk's block­buster di­a­betes drug blows the doors off in obe­si­ty, prov­ing high­ly ef­fec­tive in dri­ving weight loss

5 years ago

As US da­ta for Covid-19 vac­cine loom, As­traZeneca cleans house and scraps sev­er­al asth­ma, can­cer drugs from pipeline

5 years ago

Dan O’Day’s $5B deal with Gala­pa­gos im­plodes as PhI­II tri­als col­lapse

5 years ago

FDA pan­el ad­mon­ish­es Mer­ck with a gen­tle — and rare — slap­down for rush­ing its pitch on an ac­cel­er­at­ed OK for ad­ju­vant Keytru­da in TNBC

5 years ago

Learn­ing from oth­er­s' mis­takes, low-pro­file mi­croR­NA biotech looks to prove it­self in the clin­ic

5 years ago

Bris­tol My­ers Squibb pulls the cur­tain on PhI­II da­ta to back Op­di­vo in the ad­ju­vant set­ting

5 years ago

KalVista sees a win in PhII for the rare ge­net­ic dis­or­der HAE as it con­tin­ues to chart a post-Mer­ck course

5 years ago

Re­gen­eron stum­bles in PhI Lib­tayo com­bo study as safe­ty con­cerns force sus­pen­sion

5 years ago

Two years af­ter in­vestor pan­ic, Avro­bio touts 100% re­sponse as they look to chart a path to­ward ap­proval

5 years ago

PTC whiffs on an­oth­er Duchenne study, plans to go to FDA again any­way

5 years ago
FDA+
First page Previous page 176177178179180181182 Next page Last page
A service from the Financial Times